MTOR and cancer: It is intriguing to speculate that cancers with Nrf2 pathway activation may be vulnerable to coordinate mTOR and autophagy inhibition and RIPK- and ROS-mediated necroptosis, and that inactivation of RIPKs and necroptosis is a mechanism of resistance to cancer therapy.